Live genetically attenuated malaria vaccine
AssigneesSeattle Biomedical Research Institute, The Walter and Eliza Hall Institute of Medical Research
InventorsStefan H.I. Kappe, Kai-Uwe C. Matuschewski, Ann-Kristin Mueller, Kelley van Buskirk, Mehdi Labaied, Ahmed Sayed Ibrahim Aly, Alan Frederick Cowman, Alexander Gerd Maier
Life of this patent
Estimating the term…
Abstract
Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.
Claims5
A live Plasmodium falciparum organism that is genetically engineered to disrupt a liver-stage-specific gene function, wherein the liver-stage-specific gene is at least one of UIS3, UIS4, LSA-1, p52, p36, Etramp “Y”, Etramp “Z”, SAP1, FabI, and FabG.
A method for inoculating a human subject to confer protective immunity against subsequent exposure to Plasmodium falciparum, comprising administering to a human subject a live Plasmodium falciparum organism that is genetically engineered to disrupt a liver-stage-specific gene function, wherein the liver-stage-specific gene is at least one of UIS3, UIS4, LSA-1, p52, p36, Etramp “Y”, Etramp “Z”, SAP1, FabI, and FabG.
Dependencies are inferred from the claim text.